TICKERNERD
Menu
TMOTMOHealthcare · Diagnostics & Research

TMO Stock Forecast: Thermo Fisher Scientific, Inc. Price Predictions for 2026-2027

Last close, 19 Aug 2026
$614
+4.16% on the day

The 28 Wall Street analysts covering Thermo Fisher Scientific, Inc. hold a median 12-month price target of $643 — +4.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 19 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$216.5B
Ticker Nerd rank
82 / 100
Median analyst target
$643
Analysts covering
28
Total return, dividends reinvested
1W
+1.7%
1M
+15.2%
YTD
+6.1%
1Y
+23.6%
From 52W high
−3.9%
From 52W low
+40.1%
$438
$638
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TMO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Thermo Fisher Scientific, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Aug 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
95
Value
90
Revisions
88
Momentum
80
Quality
78
Growth
64
Issuance
50
Accruals
35
Size
1

Volatility (95): The share price has been relatively steady.

Accruals (35): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TMO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TMO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$500$600$700$800Oct 25Jan 26Apr 26Jul 26TMOHigh $750Median $643Low $520

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says28 analysts
22 Buy6 Hold0 Sell
Low $520Median $643High $750

The green dot is the last close — the median target sits +4.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
27 July 2026Morgan StanleyMaintainsOverweight$620 → $650
27 July 2026Piper SandlerMaintainsNeutral$510 → $600
24 July 2026BarclaysMaintainsOverweight$625 → $650
24 July 2026RBC CapitalMaintainsSector Perform$490 → $580
6 July 2026Evercore ISI GroupMaintainsOutperform$575 → $570
6 July 2026Evercore ISI GroupMaintainsOutperform—
26 June 2026BernsteinReinstatesMarket Perform$520
11 June 2026Piper SandlerInitiatesNeutral—
3 June 2026HSBCDowngradeHold—
2 June 2026Wolfe ResearchAssumesOutperform$535
8 May 2026Wells FargoMaintainsOverweight—
24 Apr 2026BairdMaintainsOutperform—
24 Apr 2026StifelMaintainsBuy—
14 Apr 2026BarclaysMaintainsOverweight—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
30 Jan 2026BarclaysMaintainsOverweight—
30 Jan 2026CitigroupMaintainsBuy—
30 Jan 2026TD CowenMaintainsBuy—
9 Jan 2026StifelMaintainsBuy—
7 Jan 2026TD CowenMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TMO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TMO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.0%
Analysts raising
22
Analysts cutting
0
Fundamentals

Thermo Fisher Scientific, Inc. (TMO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
31.6×

Cheaper than 25% of US stocks

Price / sales
4.7×

Cheaper than 27% of US stocks

Price / book
4.1×

Cheaper than 27% of US stocks

EV / EBITDA
21.7×

Cheaper than 15% of US stocks

Growth & margins
Revenue growth (YoY)
10.5%

Higher than 54% of US stocks

Earnings growth (YoY)
7.4%

Higher than 45% of US stocks

Gross margin
40.7%

Higher than 51% of US stocks

Operating margin
18.8%

Higher than 77% of US stocks

Net margin
15.0%

Higher than 78% of US stocks

Returns & dividend
Return on equity
13.5%

Higher than 72% of US stocks

Return on assets
5.1%

Higher than 77% of US stocks

Dividend yield
0.3%

Higher than 6% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TMO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
TMOThermo Fisher Scientific, Inc.$216.5B
82
DHRDanaher Corp.$149.4B
72
IDXXIDEXX Laboratories, Inc.$44.9B
92
NTRANatera, Inc.$44.9B
79
AAgilent Technologies, Inc.$44.1B
88
IQVIQVIA Holdings, Inc.$41.0B
94
WATWaters Corp.$40.8B
48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Thermo Fisher Scientific, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TMO news & analysis

Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside

Seeking Alpha · 16 Aug 2026positive

Seeking Alpha rates Thermo Fisher Scientific a Buy, citing accelerating organic growth and improving Pharma and Biotech end markets. The company's recent acquisitions of Clario and Solventum's Filtration and Separation business expand its capabilities, and Q2 2026 results showed 10% revenue growth, 5% organic growth, and improved margins.

Why it matters — A TMO watcher would care because the report highlights strengthening biopharma demand and strategic acquisitions that expand the company's capabilities and share of customer spending.

Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist

Business Wire · 12 Aug 2026neutral

Astorg has completed its acquisition of Thermo Fisher Scientific's global microbiology business. The business will now operate as an independent company under CEO Dirk Bontridder and will launch under a new corporate brand later in 2026.

Why it matters — TMO watchers will care because this marks the completion of a divestiture that removes a diagnostics business segment from Thermo Fisher's portfolio, signalling a shift in its scope.

Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg

Business Wire · 12 Aug 2026neutral

Thermo Fisher Scientific announced it has completed the sale of its microbiology business to private equity firm Astorg for approximately $1.075 billion, comprising cash and a $50 million seller note. The business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing.

Why it matters — A completed divestiture of this scale reshapes Thermo Fisher's portfolio and product focus, making it relevant for shareholders tracking the company's strategic composition.

Thermo Fisher eyes 15%-20% India customer growth on biopharma research, manufacturing boost

Reuters · 10 Aug 2026positive

Thermo Fisher Scientific's India unit head said the company is targeting a 15%-20% increase in its customer base in India over the next five years, driven by the growth of India's biopharma research and manufacturing ecosystem.

Why it matters — A growing customer base in India's expanding biopharma research and manufacturing sector points to potential demand for Thermo Fisher's offerings in a key emerging market.

Thermo Fisher Raises 2026 Outlook After Strong Second-Quarter Results

Zacks Investment Research · 3 Aug 2026positive

Thermo Fisher Scientific raised its 2026 outlook after reporting second-quarter earnings and revenues that exceeded expectations. The company attributed the update to stronger customer activity, better acquisition performance, and improved operating leverage.

Why it matters — For TMO watchers, an upward revision to the 2026 outlook signals the company's improving operational momentum and confidence in the quarters ahead.

FAQ

Frequently asked questions about TMO stock

What is the TMO stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Thermo Fisher Scientific, Inc. have a median 12-month price target of $643, with estimates ranging from $520 to $750. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TMO stock a buy right now?

Of the 28 analysts covering Thermo Fisher Scientific, Inc., 22 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Thermo Fisher Scientific, Inc. 82 out of 100 across roughly 4,600 US stocks as at 19 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TMO?

As at 19 Aug 2026, Thermo Fisher Scientific, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (95 of 100).

Will TMO stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +4.7% from the last close, and Ticker Nerd's factor model ranks Thermo Fisher Scientific, Inc. 82 out of 100 as at 19 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TMO stock forecast for 2030?

No analyst covering Thermo Fisher Scientific, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $520 to $750 over the next 12 months.

How has TMO stock performed over the past year?

Thermo Fisher Scientific, Inc. returned +23.6% over the 12 months to 19 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Thermo Fisher Scientific, Inc. do?

Thermo Fisher Scientific Inc. is a life sciences and laboratory solutions company that provides the tools and services used in research, diagnostics, and biopharmaceutical manufacturing.

What is the latest news on TMO?

The most recent item we track (Seeking Alpha, 16 Aug 2026): "Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside". Seeking Alpha rates Thermo Fisher Scientific a Buy, citing accelerating organic growth and improving Pharma and Biotech end markets. The company's recent acquisitions of Clario and Solventum's Filtration and Separation business expand its capabilities, and Q2 2026 results showed 10% revenue growth, 5% organic growth, and improved margins.

Company

About Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific Inc. is a life sciences and laboratory solutions company that provides the tools and services used in research, diagnostics, and biopharmaceutical manufacturing. Its portfolio spans analytical instruments, laboratory equipment, reagents, consumables, software, and specialized services that support scientific workflows from sample preparation and analysis to clinical testing and production. The company serves pharmaceutical and biotechnology firms, hospitals, clinical laboratories, universities, research institutions, and industrial customers across environmental and quality-control applications. Thermo Fisher Scientific operates through four main businesses: Analytical Instruments, Laboratory Products and Biopharma Services, Life Sciences Solutions, and Specialty Diagnostics. It plays a central role in the global scientific infrastructure by supplying products and services that help customers generate data, improve laboratory productivity, and support research and diagnostic operations worldwide.

CEO Mr. Marc N. Casper · 125,000 employees · United States · https://www.thermofisher.com